Autoimmune disease testing market to be valued at $12.1b by 2033

One growth driver includes the rising prevalence of autoimmune diseases.

The global autoimmune disease testing market is estimated to reach $12.1b by 2033 at a compound annual growth rate of 8.6%, according to Allied Market Research.

The sector’s expansion is attributed to the increasing prevalence of autoimmune diseases, advancements in diagnostic technologies, and the rising awareness of early diagnosis.

“By disease type, the rheumatoid arthritis segment has a significant market share due to the rise in prevalence of clinical importance within the autoimmune disease testing market,” the report said.

By end user, the clinical laboratories segment plays a key role in the market by processing and analysing complex autoimmune disease tests that require precise, standardised procedures.

The widespread presence and accessibility of these laboratories also contributed to the segment’s growth.